Highbridge Capital Management’s Neurogene NGNE Stock Holding History

Highbridge Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-7,351	Closed	-$397K	–	261
2019 Q1	$397K	Sell	7,351 -30,438	-81%	-$1.54M	0.01%	323
2018 Q4	$1.63M	Buy	37,789 +13,784	+57%	+$671K	0.05%	241
2018 Q3	$1.41M	Buy	24,005 +9,574	+66%	+$565K	0.03%	360
2018 Q2	$765K	Buy	+14,431	New	+$3.76M	0.02%	510
2016 Q4	–	Sell	-1,023	Closed	-$274K	–	1486
2016 Q3	$274K	Buy	+1,023	New	+$206K	﹤0.01%	1050
2015 Q4	–	Sell	-1,419	Closed	-$399K	–	1693
2015 Q3	$399K	Buy	+1,419	New	+$327K	0.01%	1124

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Highbridge Capital Management's NGNE Position: Q2 2019 in Review

Highbridge Capital Management sold out of Neurogene (NGNE) in Q2 2019, closing a stake of 7,351 shares — an estimated $397K sold.

Highbridge Capital Management first reported a position in NGNE in Q3 2015 and held it in 6 quarters. The position peaked at $1.63M in Q4 2018. 33 funds tracked by Wall St. Rank hold NGNE as of Q2 2019.

Highbridge Capital Management reported no remaining Neurogene position as of Q2 2019 after selling out during the quarter.
Highbridge Capital Management sold 7,351 Neurogene shares in Q2 2019, an estimated $397K.
Highbridge Capital Management first reported a position in Neurogene in Q3 2015 and held it in 6 quarters.
Highbridge Capital Management's Neurogene position peaked at $1.63M in Q4 2018.
33 funds tracked by Wall St. Rank held Neurogene as of Q2 2019.

Based on Highbridge Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.